Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 134Recruiting 83Unknown 72Not yet recruiting 42Terminated 37Active not recruiting 32Withdrawn 16Enrolling by invitation 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gallbladder Neoplasms 2Cholangiocarcinoma 1

Interventions

Specimen Handling 7Educational Status 7Cisplatin 7Standard of Care 6Interviews as Topic 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Carboplatin 5Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Drug Therapy 4lenvatinib 3camrelizumab 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Gemcitabine 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Dexamethasone 3Cytarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × OTHER × 130-nm albumin-bound paclitaxel × Clear all
NCT07310069 2025-12-30

TRANSFORM-GBC

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Enrolling by invitation
44 enrolled
Gastrointestinal

Gallbladder Neoplasms

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

The First Affiliated Hospital of Zhengzhou University

Phase 2 Enrolling by invitation
50 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡